Company / Capital Expenditures
Decoy Therapeutics Inc. Capital Expenditures History
FY2016-FY2021 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$2.6K
FY2021
5-year range
$0 / $559.4K
FY2017-FY2021
Trend
-
vs FY2020
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $559,378 to $2,600 over the past 3 years.
Based on SEC 10-K filings.
$2,600 in FY2021 with a 5-year CAGR of -49.1%.
Declined from $559,378 to $2,600 over the past 3 years.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -83.3%
- 5-Year CAGR
- -49.1%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -49.1%, indicating a declining trend.
- Peak capital expenditures was recorded in FY2018.
- Lowest capital expenditures in the period was in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -3.27 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2022 | - | - |
| FY2021 | $2.6K | - |
| FY2020 | $0 | - |
| FY2019 | - | - |
| FY2018 | $559.4K | +110.6% |
| FY2017 | $265.6K | +248.8% |
| FY2016 | $76.1K | - |
As of FY2021 · SEC 10-K · Updated Jun 24, 2026